Arcellx (ACLX) is positioned to disrupt multiple myeloma cell therapy with anito-cel, leveraging superior efficacy, safety, ...

Despite negative equity, Amneal raised its operating cash flow guidance for FY25. Read why I agree with Wall St., which is ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Republican leaders in the U.S. House who have struggled to come up with a way to address spiraling health insurance costs ...

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial ...